Search

ATMPs and CAR-T: the uptake challenge

Advanced therapy medicinal products (ATMPs) are a game changer for improving the life of patients with severe to life-threatening diseases. In hematology, for instance, CAR T cell therapy has shown promising results in tackling different blood cancers.

Read more

Promising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.

Read more

EHA-MSH Hematology Tutorial

EHA is joining forces with the Malaysian Society of Haematology (MSH) to organize the EHA-MSH Hematology Tutorial on Hodgkin Lymphoma.

Read more

The past and future of the EU Blood, Tissues and Cells legislation

Photo credit: Ineke Oostveen

Blood, tissues and cells (BTC) are used in medicine and in hematology on a daily basis.

Read more

EHA2025 delegate services

EHA is pleased to introduce delegate services for the upcoming EHA2025 Congress—services that registered participants can use prior, during, or after the event. Special airfare discount

Enjoy a discounted flight rate and join us in Milan.

Read more

EHA welcomes European Parliament backing for SoHO legislation

EHA welcomes the European Parliament’s backing for SoHO legislation that puts patient safety and supply sustainability first.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more